据一项Ⅱ／Ⅲ期临床研究的结果，OXiGENE公司的高浓度甲氧氯普胺（metoclopramide）制剂Sensamide是不宜进行手术的非小叶细胞肺癌（NSCLC）病人进行放射治疗时的一种有效的致敏剂。进入这一多国、随机研究的有218例病人，其中108例只接受放疗；110例接受放疗加用本品。40例接 According to a Phase II / III clinical trial, Oxygen’s high-concentration metoclopramide formulation, Sensamide, is an effective anti-inflammatory agent for non-small cell lung cancer (NSCLC) patients undergoing radiotherapy Sensitizer. Into this multinational, randomized study of 218 patients, of which 108 cases received only radiotherapy; 110 cases received radiotherapy plus the goods. 40 cases connected